Mineralys Therapeutics (MLYS) Change in Acquisitions & Divestments (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $302.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 764.29% year-over-year to $302.5 million; the trailing twelve-month figure through Mar 2026 stood at $692.5 million (up 51.86% YoY), and the FY2025 full-year result was $425.0 million, down 13.0% from the prior year.
• Change in Acquisitions & Divestments rose to $302.5 million in Q1 2026, from $165.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $302.5 million in Q1 2026 to a low of $22.5 million in Q1 2023.
• A 5-year average of $103.8 million and a median of $71.2 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments slumped 48.15% in 2025 and soared 764.29% in 2026, its largest moves.
• Tracing MLYS's Change in Acquisitions & Divestments over 5 years: stood at $50.0 million in 2022, then advanced by 30.0% to $65.0 million in 2023, then jumped by 126.92% to $147.5 million in 2024, then advanced by 11.86% to $165.0 million in 2025, then surged by 83.33% to $302.5 million in 2026.
• Business Quant data shows MLYS's Change in Acquisitions & Divestments at $302.5 million in Q1 2026, $165.0 million in Q4 2025, and $150.0 million in Q3 2025.